Medical/Pharmaceuticals
Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
* Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. * Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑reso...
2026-06-01 20:00
4443
Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
* >10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals. * 50% extended upper mass range and comprehensive suite of structural tools advance th...
2026-06-01 20:00
5105
Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration
Biond Biologics and Guangzhou-Israel Biotechnology Fund (GIBF) Announce Strategic Investment and Joint Venture to Advance First-in-Class Oncology Programs in China MISGAV, Israel and GUANGZHOU, China, June 1, 2026 /PRNewswire/ -- Biond Biologics Ltd., a private clinical-stage biotechnology compa...
2026-06-01 19:00
3781
Ebola disease in Democratic Republic of Congo: MSF scales up response to a rapidly evolving outbreak
HONG KONG, June 1, 2026 /PRNewswire/ -- In eastern Democratic Republic of Congo (DRC), people have been living through insecurity and with an under-resourced health system for years. The Ebola disease outbreak due to the Bundibugyo virus – which does not yet have approved vaccines or specific tre...
2026-06-01 18:06
5634
Driving Innovation, Empowering Partners: ACROBiosystems Showcases Comprehensive CGT Solutions Anchored by GMP Capabilities at Bio Korea 2026
SEOUL, South Korea, June 1, 2026 /PRNewswire/ -- ACROBiosystems, a biotechnology company positioning itself as a cornerstone of the global biopharmaceutical and healthcare industries, participated in Bio Korea 2026. The event brought together global pharmaceutical firms, biotech companies, inves...
2026-06-01 13:30
4776
Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema
HANGZHOU, China, SHANGHAI and BOSTON, June 1, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that its internally developed Class 1 innovative drug candi...
2026-06-01 08:00
5007
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
TAIPEI, June 1, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today highlighted a strategic vision detailed by its found...
2026-06-01 08:00
4343
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels Combination of elisrasib with pembrolizumab achieves an ORR of 81.3% in first-line KRAS G12C–mutant NSCLC (n=48) across all PD-L1 expression ...
2026-06-01 08:00
3774
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
CHENGDU, China, May 31, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug con...
2026-05-31 08:00
8525
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05, evaluating...
2026-05-30 22:01
10152
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-genera...
2026-05-30 21:51
9314
Duke-NUS graduates biggest class yet, with new doctors drawn from business, engineering and the humanities
At his first graduation as Dean, Patrick Tan presides over a record class of 135 graduates, with Guest of Honour Mdm Rahayu Mahzam and keynote speaker Dr Robert Califf SINGAPORE, May 30, 2026 /PRNewswire/ -- From engineers and business graduates to literature and communications majors, Duke-NUS ...
2026-05-30 21:01
6501
XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies
BOSTON, May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc. has achieved substantial progress, and that XtalPi has received the second...
2026-05-29 22:10
7529
CooperVision Names Muru Annamalai as President, Asia-Pacific
Experienced Global Healthcare Leader to Guide Growth Across the Region SINGAPORE, May 29, 2026 /PRNewswire/ -- CooperVision has named Muru Annamalai as President, Asia-Pacific, effective June 1. He brings more than two decades of global leadership experience across the pharmaceutical and healthca...
2026-05-29 20:05
4945
Doctors at Omotesando Helene Clinic Publish New Study on Long-Term Safety Surveillance Following High-Dose Intravenous MSC Administration
Continuing clinical data analysis and academic publication in regenerative medicine and ATMP as the Tokyo clinical hub within Helene Bio Group TOKYO, May 29, 2026 /PRNewswire/ -- Medical Corporation HELENE Omotesando Helene Clinic, located in Minato-ku, Tokyo, is pleased to announce that a resea...
2026-05-29 13:50
4927
HMS Vision Inc. and Wenzhou Medical University Announce the Expansion of Their Simulation-Based Training Center During Vision China 2026
TIANJIN, China, May 29, 2026 /PRNewswire/ -- HMS Vision Inc. announced this week at Vision China 2026 the expansion of the HelpMeSee Simulation-based Eye Surgery Training Program at the Eye Hospital of Wenzhou Medical University (WMU). Since the collaboration began in 2018, the program has grown ...
2026-05-29 09:02
4864
Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
* Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented. * The efficacy data highlight how the combination of elacestrant and capivasertib has the potential to address key resistance mechanisms for pa...
2026-05-29 00:02
5334
Haier Biomedical Achieves Double No. 1 Ranking in Euromonitor's Global Life Science Lab Equipment Report, Caps Three-Phase Global Expansion
QINGDAO, China, May 28, 2026 /PRNewswire/ -- Haier Biomedical
2026-05-28 21:25
8660
PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
IRVINE, Calif., May 28, 2026 /PRNewswire/ -- PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell therapy, have been selected for an oral presentation a...
2026-05-28 19:00
3815
REJUVANT OUTPERFORMS ALL TESTED SUPPLEMENTS, INCLUDING STANDARD AKG AND NAD+ IN LANDMARK AGING CELL STUDY
FERNANDINA BEACH, Fla., May 28, 2026 /PRNewswire/ -- Ponce De Leon Health (PDLH), a commercial stage longevity company focused on the extension of healthspan and the reduction of biologic age in humans and animals, today highlighted the publication of alandmark peer-reviewed study in the scientif...
2026-05-28 18:38
4333
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
MetaOptics and Elsoft partner to scale next-generation semiconductor optics manufacturing equipment
[Picked up by 286 media titles]
2026-07-30 18:15Most Read
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
2026-07-30 10:45
13240
